Format

Send to:

Choose Destination
See comment in PubMed Commons below
Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15.

Monoclonal antibody therapies against anthrax.

Author information

  • 1Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. zchen@niaid.nih.gov

Abstract

Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.

KEYWORDS:

Bacillus anthracis; a cocktail of mAbs; anti-EF mAbs; anti-LF mAbs; anti-PA mAbs; anti-capsule mAbs; post-exposure treatment of anthrax

PMID:
22069754
[PubMed - indexed for MEDLINE]
PMCID:
PMC3202866
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Write to the Help Desk